Supplements
This product scores low overall due to limited clinical evidence beyond acute GH/IGF-1 increases (e.g., Teichman et al. 2006: 30-60 mcg/kg CJC-1295 doubled GH for days in phase 1, n small; no body comp RCTs) and significant FDA safety flags (Category 2 nomination, cardiac risks, impurities). Typical doses (100-300 mcg each/night SC) align with studies but lack long-term data in healthy users. Compounded peptides face sterility recalls and immunogenicity risks, outweighing anecdotal benefits like
Avoid Peptual CJC-1295 + Ipamorelin due to unapproved status, FDA safety warnings, and limited evidence beyond GH surrogates. Risks of cardiac issues, impurities, and inefficacy for claims outweigh potential benefits. Opt for lifestyle or approved therapies instead.